Showing results (51-60 of 155) with videos related to

Sort By:
Pageof 16
Oncotarget|April 19, 2017
MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lungRaphaël Saffroy, Vincent Fallet, Nicolas Girard, et al.
Cancer Treatment and Research Communications|January 16, 2022
Survival of clinical stage III NSCLC according to therapeutic strategy: Relevance of the tumor board decision in the era of immunotherapyJustin Benet, Anne-Claire Toffart, Pierre-Yves Brichon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 7, 2012
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trialMichaël Duruisseaux, Laurence Baudrin, Elisabeth Quoix, et al.
Lung Cancer (Amsterdam, Netherlands)|October 9, 2012
Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME)Philipp A Schnabel, Egbert Smit, Javier de Castro Carpeño, et al.
Current Medical Research and Opinion|August 12, 2020
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated <i>EGFR</i>-mutated metastatic non-small-cell lung cancerKiyotaka Yoh, Shinji Atagi, Martin Reck, et al.
Lung Cancer (Amsterdam, Netherlands)|July 17, 2012
Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: a retrospective study of 300 patientsHélène Nagy-Mignotte, Pascale Guillem, Lucile Vignoud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2014
Lung squamous cell carcinomas with basaloid histology represent a specific molecular entityChristian Brambilla, Julien Laffaire, Sylvie Lantuejoul, et al.
Lung Cancer (Amsterdam, Netherlands)|January 11, 2015
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensusFederico Cappuzzo, Denis Moro-Sibilot, Oliver Gautschi, et al.
Oncoimmunology|April 15, 2025
Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancerFabrice Barlesi, Adrien Dixmier, Didier Debieuvre, et al.
Lung Cancer (Amsterdam, Netherlands)|January 19, 2016
Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME studyEgbert Smit, Denis Moro-Sibilot, Javier de Castro Carpeño, et al.
Pageof 16